Transforming Pharmacovigilance: Integrating Pharmacogenomics and AI for Enhanced Drug Safety and Personalized Medicine

Apeksha S. Bopshetty [1], Akshata S. Zalte [2] , Anjali U. Mundhe [3], Arpita V. Khapare [4], Bhumika M. Kothari [5], Manisha R. Jawale [6], Somnath Vibhute [7], Shivshankar M. Nagrik [8] ,Shirish Jain [9]

[1,2,3,4,5] B. Pharm, Rajarshi Shahu College of Pharmacy ,Buldhana, Maharashtra, India.

[6] Assoc Prof. M. Pharm, Department of Pharmacology , Rajarshi Shahu College of Pharmacy ,Buldhana, Maharashtra, India.

[7]Assoc Prof. M.Pharm, Ph.D. Department of Pharmaceutics , Rajarshi Shahu College of Pharmacy ,Buldhana, Maharashtra, India.

[8] M. Pharm, Department of Pharmaceutics , Rajarshi Shahu College of Pharmacy ,Buldhana, Maharashtra, India.

[9] Principal, M. Pharm, Ph.D. Department of Pharmacology , Rajarshi Shahu College of Pharmacy ,Buldhana, Maharashtra, India.

Abstract

Adverse drug reactions (ADRs) pose significant challenges to global health, contributing to morbidity, mortality, and escalating healthcare costs. With ADRs accounting for 5-7% of hospital admissions and being a leading cause of death in some regions, there is an urgent need for improved predictive systems and preventive strategies. Pharmacovigilance, the science of monitoring drug safety, traditionally relies on passive and active surveillance methods, which often fail to account for genetic variations that influence drug metabolism and response. Pharmacogenomics, the study of how genetic makeup affects drug response, offers a transformative approach to enhance drug safety monitoring. By integrating pharmacogenomic data into clinical workflows, healthcare providers can preemptively identify patients at risk of ADRs, thereby tailoring treatments to individual genetic profiles. This review highlights the fundamental principles of pharmacogenomics, including gene-drug interactions and the clinical significance of genetic biomarkers. It discusses the limitations of traditional pharmacovigilance systems, particularly their inability to detect genetically predisposed ADRs, and presents case studies illustrating the consequences of delayed integration of genetic data. The review emphasizes the role of pharmacogenomic testing in both pre-marketing and post-marketing phases, showcasing successful implementations in electronic health records (EHRs) and clinical decision support systems (CDSS).Furthermore, the review explores the development of genetic risk scores and the application of machine learning to predict ADRs based on genetic data. It addresses regulatory and ethical considerations, including data privacy and the need for standardized testing protocols. Finally, the review envisions a future where personalized pharmacovigilance, powered by AI and big data, enables proactive safety monitoring tailored to individual patients. By leveraging pharmacogenomics, the healthcare system can significantly enhance drug safety, reduce healthcare costs, and improve patient outcomes, marking a pivotal shift towards precision medicine in pharmacovigilance.

Key Words: Pharmacovigilance , Pharmacogenomics , Adverse Drug Reactions , Gene-Drug Interactions , Healthcare Disparities.

1. INTRODUCTION

Adverse drug reactions (ADRs) are unintended, harmful reactions to drugs administered at standard doses for therapeutic purposes. They are a major cause of morbidity and mortality globally. ADRs contribute significantly to hospital admissions and healthcare costs. It is estimated that ADRs account for 5–7% of all hospital admissions and occur in up to 20% of hospitalized patients [1]. Moreover, the World Health Organization (WHO) identifies ADRs as one of the top ten leading causes of death in some countries, emphasizing their widespread impact [2].ADR incidence tends to be higher among the elderly and polypharmacy patients due to altered pharmacokinetics and drug interactions. The burden is also economic: in the United States alone, ADR-related costs are projected to exceed $30 billion annually [3]. These statistics underscore the urgent need for better predictive systems and preventive strategies. Pharmacovigilance refers to the science and activities involved in the detection, assessment, understanding, and prevention of adverse effects or any drug-related problems. The goal is to ensure safer therapeutic practices through the continual monitoring of marketed drugs [4]. Post-marketing surveillance is particularly vital because clinical trials typically exclude vulnerable populations and may not reveal rare ADRs due to limited sample sizes and shorter durations [5]. Modern pharmacovigilance systems use both passive (e.g., spontaneous reporting) and active (e.g., database mining, cohort event monitoring) strategies. Recent advances include the use of machine learning and artificial intelligence in pharmacovigilance systems to enhance signal detection efficiency [6].

Pharmacogenomics

Pharmacogenomics is the study of how an individual's genetic makeup affects their response to drugs. Unlike pharmacogenetics, which typically focuses on single gene-drug interactions, pharmacogenomics evaluates genome-wide interactions and their influence on pharmacodynamics and pharmacokinetics [7]. Genetic polymorphisms in drug-metabolizing enzymes (e.g., CYP450), transporters, and receptors can influence drug efficacy and toxicity. This field holds promise for tailoring medical treatment to individual genetic profiles, often referred to as personalized or precision medicine. Genes such as *CYP2D6*, *TPMT*, and *HLA-B* are already used clinically to guide therapy decisions for drugs like codeine, azathioprine, and abacavir [8].The integration of pharmacogenomics into pharmacovigilance represents a proactive rather than reactive approach to drug safety. Traditional pharmacovigilance often identifies ADRs only after they occur. In contrast, pharmacogenomics enables *pre-emptive*

identification of patients at risk before drug administration [9]. By incorporating pharmacogenomic screening into clinical workflows, healthcare providers can predict ADR susceptibility and avoid harmful drug-gene interactions. For example, genotyping for *HLA-B* alleles can prevent life-threatening hypersensitivity reactions to drugs like abacavir and carbamazepine [10]. Additionally, integrating genomic data into electronic health records (EHRs) can support clinical decision-making and provide real-time alerts during prescribing.Furthermore, regulatory bodies such as the U.S. FDA and EMA now recommend or require pharmacogenomic testing for certain medications, reflecting the increasing institutional support for this integration [11].



Figure 1. Pharmacogenetic Profiles Based on CYP2D6 Variants and Their Impact on Drug Metabolism.

The figure 1. illustrates the relationship between CYP2D6 genetic variants and drug metabolism phenotypes—extensive (normal), ultrarapid, and poor metabolizers. Individuals with normal CYP2D6 function (extensive metabolizers) efficiently process drugs such as fluoxetine, clonidine, and sertraline. Ultrarapid metabolizers, often due to gene duplication (e.g., CYP2D6L), may excessively metabolize these drugs, potentially reducing therapeutic efficacy or increasing active metabolite toxicity. In contrast, poor metabolizers, typically harboring non-functional alleles like *4/*5, exhibit impaired drug clearance, leading to drug accumulation and heightened risk of adverse effects. These variations underscore the importance of personalized pharmacotherapy guided by pharmacogenetic testing.

2. FUNDAMENTALS OF PHARMACOGENOMICS

2.1 Basic Principles: Gene–Drug Interactions

Pharmacogenomics explores the relationship between an individual's genome and their response to specific drugs. Gene–drug interactions arise when variations in DNA alter the pharmacodynamics (what the drug does to the body) or pharmacokinetics (what the body does to the drug) of a compound. Key mechanisms include altered drug absorption, metabolism, and elimination pathways, often influenced by enzymes, transporters, or receptors encoded by specific genes. For instance, patients with reduced-function variants in the *TPMT* gene can accumulate toxic levels of thiopurines due to decreased metabolism, while those with certain *VKORC1* or *CYP2C9* variants may require lower doses of warfarin to avoid bleeding risks. These interactions underscore the value of genetic screening in prescribing to predict treatment efficacy and prevent harm [12,13].

2.2 Common Gene Polymorphisms Affecting Drug Metabolism (e.g., CYP450 Family)

In table 1 summarizes the most clinically significant cytochrome P450 (CYP450) gene polymorphisms that influence drug metabolism. These genetic variants—particularly within CYP2D6, CYP2C9, CYP2C19, and CYP3A4—can significantly alter enzyme activity, classifying individuals into different metabolizer phenotypes: poor, intermediate, extensive (normal), or ultra-rapid. Such phenotypic variability affects the pharmacokinetics and efficacy of commonly prescribed drugs, including codeine, warfarin, clopidogrel, and various psychotropic and cardiovascular agents. Notably, ultra-rapid metabolizers may experience toxicity due to increased drug activation (e.g., morphine from codeine), while poor metabolizers may exhibit reduced therapeutic response. The table also highlights the role of copy number variations (CNVs), which further complicate genotype-to-phenotype predictions. In response to these genetic differences, regulatory bodies like the FDA and CPIC have issued pharmacogenetic dosing guidelines to enhance drug safety and therapeutic outcomes.

Table 1. Common CYP450 Gene Polymorphisms and Their Clinical Relevance

Gene	Common Variants / Polymorphisms	Metabolizer Phenotypes	Affected Drugs	Clinical Implicatio	Ref.
CYP2D6	Gene duplications, *3, *4, *5, *10	Poor, Intermediate, Extensive, Ultra-rapid	Codeine, Tamoxifen, Antidepressants	Ultra-rapid: Risk of toxicity (e.g., morphine overdose); Poor: Reduced efficacy	[14]
CYP2C9	*2, *3	Poor, Intermediate, Extensive	Warfarin	Decreased metabolism leads to bleeding risk; dosing adjustment needed	[15]
CYP2C19	*2, *3 (loss-of-function)	Poor, Intermediate, Extensive, Ultra-rapid	Clopidogrel, PPIs	Poor metabolizers may have reduced antiplatelet effect; consider alternative therapy	[16]

CYP3A4	*1B, *22	Extensive (normal), possible altered activity	Statins, Calcium Channel Blockers, Tacrolimus	Variable response and toxicity; clinical impact less well-defined than other CYPs	-
Copy Number Variants (CNVs)	Gene deletions, duplications	Affects expression and phenotype	Multiple CYP-related drugs	Adds complexity to phenotype prediction; requires advanced testing methods	[17]

2.3 Genetic Biomarkers and Their Clinical Significance

Pharmacogenomic biomarkers are genetic indicators used to predict therapeutic response or adverse reactions. Their clinical significance is immense in oncology, cardiology, psychiatry, and infectious disease.

Examples include:

HLA-B*57:01: Associated with hypersensitivity to abacavir in HIV treatment [18].

UGT1A1*28: Linked to increased risk of neutropenia in patients receiving irinotecan [19].

DPYD variants: Lead to severe toxicity in patients treated with fluoropyrimidines like 5-FU [20].The FDA has integrated over 400 drug labels with pharmacogenomic information, emphasizing the growing reliance on these biomarkers to improve safety and efficacy.

2.4 Pharmacogenomics vs Pharmacogenetics: Distinction and Relevance

While used interchangeably, pharmacogenetics traditionally refers to the study of single gene–drug interactions, whereas pharmacogenomics encompasses genome-wide assessments. The

former is suitable for well-defined gene-drug pairs (e.g., CYP2C9-warfarin), while the latter includes complex, polygenic traits and multi-gene interaction networks.The relevance of both lies in tailoring therapy: Pharmacogenetics supports immediate clinical decisions for drugs with known risk profiles. Pharmacogenomics fuels precision medicine through genome-wide association studies (GWAS) and next-gen sequencing (NGS), discovering new targets and improving predictive models [21].



Figure 2. Overview of Single Gene–Drug Interactions in Pharmacogenetics.

This figure 2 illustrates the dual roles of pharmacokinetics and pharmacodynamics in determining drug response, and how genetic variations contribute to these processes. Single gene–drug interactions involve variations in specific genes that influence either drug metabolism (pharmacokinetics) or drug targets (pharmacodynamics). For example, variations in CYP2C9 affect warfarin metabolism, while polymorphisms in VKORC1 influence warfarin's pharmacodynamic target. Genetic variants in drug-metabolizing enzymes (DMEs) and transporters—such as SLCO1B1, CYP2C19, and CYP2C9—can alter drug exposure and efficacy. Similarly, variations in target receptors (e.g., RYR1 for volatile anesthetics) or immune system genes (e.g., HLA-B alleles for abacavir, allopurinol, and carbamazepine) can lead to off-target or immune-mediated adverse drug reactions. These single gene variations are central to the development of personalized medicine strategies in pharmacotherapy.

3. CURRENT DRUG SAFETY MONITORING APPROACHES

3.1 Overview of Traditional Pharmacovigilance Systems

Traditional drug safety monitoring is centered on pharmacovigilance systems such as spontaneous reporting, active surveillance, and post-marketing surveillance. The spontaneous reporting system (SRS) is the cornerstone of most national and international pharmacovigilance programs, where healthcare providers, patients, or manufacturers voluntarily report adverse drug events (ADEs). Systems such as the FDA Adverse Event Reporting System (FAERS) or EudraVigilance in the EU have historically served as repositories for identifying potential safety signals. Active surveillance complements spontaneous reporting through systems like sentinel networks, electronic health records (EHR) mining, and prescription event monitoring (PEM), which proactively monitor predefined populations for ADRs after drug approval [22,23]. Despite their utility, these systems are limited by underreporting, reporting bias, and inability to identify subpopulation-specific risks particularly those rooted in genetic variation [24].

3.2 Limitations in Detecting Genetically Predisposed ADRs

One of the most significant blind spots in conventional pharmacovigilance is its limited integration of pharmacogenomic data. Traditional systems are not designed to identify adverse reactions linked to pharmacogenetic polymorphisms that modulate drug metabolism, transport, or target interaction. A prime limitation is the non-stratified approach—treating all individuals as biologically identical, overlooking that gene variants (e.g., *CYP2D6*, *HLA-B*, *TPMT*) can dramatically affect drug response. For example, individuals with a *poor metabolizer* genotype may experience toxicity at standard doses of codeine or clopidogrel, yet these variations remain undetected unless pharmacogenetic testing is proactively done [25].

Furthermore, ethnic and population differences in allele frequencies (e.g., *HLA-B*15:02 associated with carbamazepine-induced Stevens-Johnson Syndrome in Asians) are not accounted for in most spontaneous reporting databases, which diminishes sensitivity for detecting regionally relevant ADRs [26,27].

3.3 Examples of Missed or Delayed Detection Due to Lack of Genetic Data

Several well-documented pharmacovigilance failures underscore the need for integrating pharmacogenomic insights:

Carbamazepine and HLA-B*15:02: The link between this allele and severe cutaneous adverse reactions was identified **only after many cases were reported** in Southeast Asia, despite the genetic predisposition being known earlier in research settings [28].

Abacavir and HLA-B*57:01: Hypersensitivity reactions were widely reported before the FDA mandated genetic screening, revealing how delayed integration of genetic data into routine monitoring led to avoidable toxicity [29].

Warfarin and CYP2C9/VKORC1: Variants in these genes affect dosage requirements significantly. However, many bleeding episodes and hospitalizations could have been prevented with preemptive genotyping, which was not standard in earlier pharmacovigilance practices [30].

Thiopurines and TPMT deficiency: Cases of life-threatening myelosuppression from standard doses of azathioprine or 6-mercaptopurine were only flagged after multiple reports, even though low TPMT activity was already established as a risk factor.These instances collectively highlight a systemic delay in translating **genotype-informed risk mitigation** into real-world pharmacovigilance frameworks [31].

4. INTEGRATION OF PHARMACOGENOMICS IN DRUG SAFETY

4.1 Role of Pharmacogenomic Testing in Pre-Marketing and Post-Marketing Phases

Pharmacogenomics (PGx) plays a vital role in both the **pre-marketing** and **post-marketing** phases of drug development. In the pre-marketing stage, PGx testing can uncover genetic variants that affect drug metabolism, efficacy, or toxicity. This allows pharmaceutical companies to stratify patient populations during clinical trials, optimize dosing regimens, and even repurpose failed drugs for genetically defined subgroups. For instance, the identification of *HLA-B*1502* association with carbamazepine-induced Stevens-Johnson syndrome in Asian populations prompted genotype-based exclusions during trials [32]. In the **post-marketing phase**, PGx supports surveillance for adverse drug reactions (ADRs), enhancing pharmacovigilance. Regulatory agencies such as the FDA have updated drug labels with pharmacogenomic information (e.g., CYP2C9 and VKORC1 for warfarin), reflecting real-world data on drug safety. This iterative feedback loop improves risk-benefit profiles and informs label modifications or black box warnings.PGx testing thus functions as a dynamic safety tool across a drug's lifecycle, refining both population-level and personalized therapeutic strategies [33].

4.2 Implementation in Electronic Health Records (EHRs) and Clinical Decision Support Systems (CDSS)

For pharmacogenomic data to influence clinical practice, it must be integrated into **EHRs** and paired with **clinical decision support systems (CDSS)**. CDSS can alert clinicians at the point of prescribing, flagging gene-drug interactions (GDIs) that may affect efficacy or increase ADR risk. One major effort is the Clinical Pharmacogenetics Implementation Consortium (CPIC), which provides structured guidelines that can be translated into algorithmic decision tools [34].Hospitals like St. Jude Children's Research Hospital have pioneered EHR-linked PGx programs, where patient genotype results for TPMT or CYP2D6 are stored longitudinally and auto-trigger alerts when thiopurines or opioids are prescribed [35]. Such implementations require:

- Standardized terminologies (e.g., SNOMED-CT, LOINC),
- Cross-disciplinary cooperation (IT, pharmacology, genetics),
- Long-term clinical utility validation.

As data-sharing networks like eMERGE expand, the interoperability of pharmacogenomic CDSS is improving, making it a scalable model for preventive pharmacovigilance [36].

4.3 Case Studies: Pharmacogenomic Insights Preventing ADRs

a. Warfarin

Warfarin's narrow therapeutic window has made it a classic case for PGx-driven dosing. Variants in **CYP2C9** reduce warfarin metabolism, while **VKORC1** affects sensitivity to warfarin's anticoagulant effect. PGx-guided dosing has been shown to reduce bleeding risk and time to stable INR [37].

b. Clopidogrel

Clopidogrel, an antiplatelet prodrug, requires bioactivation by **CYP2C19**. Carriers of loss-of-function alleles (*2, *3) have reduced conversion, leading to higher risk of stent thrombosis. The FDA now includes a boxed warning recommending PGx testing for patients undergoing percutaneous coronary intervention (PCI) [38].

c. Carbamazepine

One of the most striking cases of PGx saving lives involves the association between **HLA-B*1502** and carbamazepine-induced toxic epidermal necrolysis (TEN) in Asian populations. Screening for HLA-B*1502 has led to reduced incidence of this potentially fatal reaction in Taiwan and Southeast Asia, demonstrating global pharmacogenomic surveillance in action [39].

5. PHARMACOGENOMICS-GUIDED RISK PREDICTION MODELS

A. Development of Genetic Risk Scores

Genetic risk scores (GRS), also referred to as polygenic risk scores (PRS), are statistical constructs that sum the effect of multiple genetic variants to estimate an individual's predisposition to certain phenotypes—including drug response and ADRs. These scores form the foundation for predictive pharmacogenomics, particularly in stratifying patients based on susceptibility to ADRs. A growing body of work illustrates that leveraging PRS tailored for pharmacogenes (e.g., CYP2D6, HLA-B*57:01) can help clinicians identify patients at higher risk of experiencing toxicities or treatment failure. For instance, studies have shown the clinical utility of HLA genotyping in preventing hypersensitivity to abacavir and allopurinol. Recent efforts incorporate genome-wide association studies (GWAS) findings into GRS development, enabling a more quantitative assessment of risk. This expansion beyond single-gene approaches improves model granularity and predictive power [40,41].

B. Integration with Real-World Data (e.g., Biobanks, Registries)

Biobanks and healthcare registries are pivotal for advancing pharmacogenomic risk models. They provide the necessary large-scale genomic and phenotypic data to validate and refine predictive tools. For example, UK Biobank and UCORBIO have enabled the identification of genotype-ADR associations by linking genomic information with electronic health records (EHRs) and prescription data [42,43]. Such datasets facilitate discovery of rare but clinically significant ADRs, especially when stratified by population subgroups. Additionally, registries capturing longitudinal outcomes aid in assessing the real-world effectiveness of pharmacogenomics-guided interventions. Integration with registries is also essential for

ensuring population-specific model validity—especially in underrepresented groups, such as African or Southeast Asian populations, where drug responses often deviate from those observed in Caucasian cohorts [44,45].

C. Machine Learning Approaches for ADR Prediction Using Genetic Data

The integration of artificial intelligence—particularly machine learning (ML)—into pharmacogenomics has dramatically improved the ability to model complex gene-drug interactions. ML algorithms can handle the high-dimensionality and non-linear nature of genomic data, which traditional statistical models often fail to capture. Supervised learning models such as random forests, support vector machines, and neural networks are widely used to train ADR prediction systems on labeled genotype–phenotype datasets. For example, recent models have achieved robust sensitivity in predicting warfarin dose requirements and clopidogrel responsiveness based on combined pharmacogenomic and clinical features [46].

Emerging unsupervised and deep learning techniques are also being explored to uncover latent features within genotype data and identify novel ADR clusters. Importantly, ML approaches allow for adaptive model retraining as new data from registries and biobanks become available—enhancing long-term performance and relevance.Nonetheless, challenges such as overfitting, algorithm interpretability, and limited generalizability across populations remain areas of ongoing research and development [47].

6. REGULATORY AND ETHICAL CONSIDERATIONS

6.1 Regulatory Frameworks by FDA, EMA, and Other Agencies

The global advancement of pharmacogenomics (PGx) has prompted major regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), to refine their frameworks to facilitate the safe integration of genetic data into drug development and monitoring. The FDA maintains a Pharmacogenomic Biomarkers in Drug Labeling database which includes over 400 gene-drug interactions that guide clinical decisions. Similarly, the EMA has developed guidelines for the pharmacogenomic evaluation of medicinal products to ensure consistency across the European Union [49,50]. The FDA and EMA often collaborate through working groups like the International Conference on Harmonisation (ICH) to align on validation requirements and interpretation of genetic data. However, discrepancies persist in regulatory decisions for pharmacogenomic labeling between the two agencies, leading to inconsistent patient care globally [51,52]. Emerging markets and

regional bodies such as Korea's MFDS and Japan's PMDA are also adopting tailored approaches, though harmonization with FDA/EMA remains incomplete [53].

6.2 Challenges in Data Sharing, Privacy, and Informed Consent

The ethical and legal dimensions of pharmacogenomics primarily revolve around data privacy, informed consent, and equitable access. The use of genetic data raises significant challenges, particularly in cross-border research and multinational clinical trials. Regulations such as the General Data Protection Regulation (GDPR) in Europe place strict limits on how personal genetic data can be stored, processed, and transferred, even for public health purposes [54]. Informed consent in PGx research is not merely a formality—it must account for future uses of data, incidental findings, and participant withdrawal. Traditional one-time consent models are being replaced by dynamic consent frameworks that allow ongoing interaction with participants [55]. Furthermore, there are concerns about genetic discrimination, especially in countries lacking protective legislation. In the U.S., the Genetic Information Nondiscrimination Act (GINA) offers some safeguards, but gaps remain in coverage, particularly for life and disability insurance [56].

6.3 Standardization of Pharmacogenomic Testing and Reporting

The lack of standardization in PGx testing platforms, data interpretation, and result reporting continues to hinder widespread clinical adoption. Different laboratories may use varied allelic definitions or reference databases, resulting in inconsistent results for the same patient sample [57]. Efforts toward standardization have been led by consortia such as the **Clinical Pharmacogenetics Implementation Consortium (CPIC)** and the **Dutch Pharmacogenetics Working Group (DPWG)**, both of which issue peer-reviewed guidelines to harmonize genotype-to-phenotype translations [58].Regulatory agencies are now recognizing the need for unified terminology, assay validation protocols, and software tools for automated annotation of results. A coordinated international effort, possibly under the auspices of the **World Health Organization (WHO)** or a newly formed **Global PGx Standards Board**, is being called for to unify current fragmented efforts [59].

7. CHALLENGES AND BARRIERS

7.1 Limited Genetic Data Availability in Diverse Populations

One of the most pressing issues in pharmacogenomics is the underrepresentation of ethnically diverse populations in genomic databases. The majority of pharmacogenomic studies have

focused on populations of European descent, which limits the applicability and generalizability of findings to other groups. This disparity contributes to inequities in drug efficacy and safety, particularly among African, Asian, and Indigenous populations. A lack of population-specific allelic frequency data hinders the ability to develop precise dosing guidelines and can result in increased adverse drug reactions (ADRs) or therapeutic failure in underserved communities [60].Recent efforts like the Global Alliance for Genomics and Health and initiatives targeting Asian and African genetic data (e.g., H3Africa) have made progress, but substantial gaps remain. Without more inclusive genomic data, pharmacogenomics cannot fully realize its potential to tailor drug treatments to every patient [61].

7.2 Cost and Accessibility of Pharmacogenomic Testing

The cost of pharmacogenomic (PGx) testing remains a significant barrier to widespread adoption, particularly in low-resource settings. While sequencing costs have decreased, comprehensive testing panels and the required bioinformatics support still pose financial burdens on healthcare systems and patients alike. Insurance coverage for PGx testing varies widely, with many plans not reimbursing costs unless there is clear evidence of benefit [62,63]. Moreover, implementation costs include not just the tests themselves but also infrastructure for data storage, electronic health record (EHR) integration, and clinical decision support tools. These factors limit the practical accessibility of PGx, especially in public healthcare systems or in regions with limited healthcare investment [64].

7.3 Lack of Clinician Education and Training

Healthcare providers often lack formal education or adequate training in pharmacogenomics, resulting in hesitancy to use test results in clinical decision-making. Surveys show that while clinicians are generally optimistic about PGx, many feel ill-prepared to interpret test results or to modify prescriptions based on them [65]. The absence of standardized training modules and integration into medical curricula exacerbates the issue. Even among pharmacists and genetic counselors, gaps exist in applying PGx data to real-world scenarios. The need for interdisciplinary education and continuing medical education (CME) programs is critical. Resources such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and PharmGKB provide valuable guidelines but require active engagement and training to utilize effectively [66].

7.4 Data Integration Challenges

Effective use of pharmacogenomics in clinical practice depends on seamless data integration across electronic health systems, laboratories, and clinical decision support platforms. However, PGx data are often stored in disparate systems, and interoperability remains a major barrier. Ensuring consistent terminology, integrating genomic data with EHRs, and enabling real-time clinical alerts based on test results are technically and logistically challenging [67]. Privacy concerns also complicate data integration. Storing and sharing sensitive genetic information require compliance with strict data protection regulations like HIPAA and GDPR. Additionally, health IT systems must be capable of handling large-scale, structured genomic datasets—a capability many current systems lack [68].

8. FUTURE PERSPECTIVES AND INNOVATIONS IN PHARMACOGENOMICS

8.1 Role of AI and Big Data in Enhancing Pharmacogenomic Applications

The integration of artificial intelligence (AI) and big data analytics in pharmacogenomics is reshaping the landscape of drug safety monitoring. AI-powered algorithms can analyze vast datasets from electronic health records (EHRs), genomic sequencing, and real-world evidence (RWE) to identify genetic variants associated with adverse drug reactions (ADRs) and optimize drug therapy outcomes [69]. AI systems such as natural language processing (NLP) and machine learning (ML) models are increasingly used to automate signal detection in pharmacovigilance, thus reducing human bias and improving detection accuracy. For instance, platforms like the FDA's Sentinel Initiative leverage big data analytics to conduct active surveillance of drug safety, enhancing preemptive pharmacogenomic insights [70]. Moreover, predictive AI models are being developed to forecast patient responses to drugs based on multi-omic profiles, potentially preventing harmful drug interactions before clinical manifestation. These developments suggest a future where pharmacogenomic recommendations are delivered in real-time within clinical decision support systems (CDSS), offering contextual guidance at the point of care [71].

8.2 Global Pharmacogenomic Databases and Collaborative Initiatives

Collaboration is critical for creating a robust global pharmacogenomics infrastructure. Initiatives such as PharmGKB, the Clinical Pharmacogenetics Implementation Consortium (CPIC), and the Ubiquitous Pharmacogenomics (U-PGx) project are central to aggregating and curating pharmacogenomic data across populations and ethnic groups [72,73]. These

repositories ensure equitable access to knowledge and minimize disparities in precision medicine. Moreover, recent calls for standardized data formats, open-access repositories, and international regulatory harmonization are gaining traction. The EU-ADR web platform and the WHO's VigiBase exemplify global efforts to unite data from various sources, including underrepresented regions, which enhances the generalizability and scalability of pharmacogenomic insights. Global initiatives are also fostering intersectoral collaborations between bioinformaticians, clinicians, and regulatory bodies to streamline genomic data into drug labeling and post-marketing surveillance frameworks [74].

8.3 Personalized Pharmacovigilance: Toward Precision Safety Monitoring

A paradigm shift is underway from population-level pharmacovigilance to **personalized pharmacovigilance**. This involves tailoring drug safety monitoring based on an individual's genomic, epigenetic, and environmental profile [75]. Personalized pharmacovigilance is poised to revolutionize post-marketing surveillance by integrating pharmacogenomic alerts within wearable devices, EHR-integrated risk dashboards, and mobile apps that dynamically update as patient data evolves [76]. Machine learning models can now identify previously unnoticed ADR patterns by correlating pharmacogenomic markers with longitudinal health data [77]. This enables more proactive and pre-symptomatic safety monitoring, drastically improving patient outcomes and reducing healthcare costs. The vision of a responsive, individualized pharmacovigilance ecosystem depends on interoperable data architectures, AI explainability, and ethical safeguards—especially concerning data privacy and algorithmic bias [78].

CONCLUSION

The integration of pharmacogenomics into drug safety monitoring represents a transformative advancement in the field of pharmacovigilance, addressing the critical challenge of adverse drug reactions (ADRs) that significantly impact patient safety and healthcare costs. By leveraging genetic insights, healthcare providers can proactively identify individuals at risk of ADRs, thereby tailoring therapeutic interventions to optimize efficacy and minimize harm. This shift from a reactive to a proactive approach not only enhances patient outcomes but also aligns with the principles of precision medicine, which seeks to personalize treatment based on individual genetic profiles.

Despite the promising potential of pharmacogenomics, several challenges remain. The underrepresentation of diverse populations in genomic databases, the high costs of testing, and the need for clinician education and training are significant barriers to widespread adoption. Furthermore, the integration of pharmacogenomic data into electronic health records and clinical decision support systems is essential for real-time application in clinical practice. Addressing these challenges requires collaborative efforts among regulatory agencies, healthcare providers, and researchers to establish standardized testing protocols, improve data sharing, and ensure equitable access to pharmacogenomic resources.

Looking ahead, the future of pharmacovigilance is poised for innovation through the incorporation of artificial intelligence and big data analytics. These technologies can enhance the detection of genetic variants associated with ADRs and facilitate the development of predictive models that inform clinical decision-making. As personalized pharmacovigilance evolves, it promises to revolutionize drug safety monitoring by integrating genomic data into everyday clinical practice, ultimately leading to safer and more effective therapeutic strategies.

In conclusion, the "Gene-ius Move" towards leveraging pharmacogenomics in drug safety monitoring is not merely an enhancement of existing practices; it is a paradigm shift that holds the potential to significantly reduce the burden of ADRs, improve patient care, and foster a more personalized approach to medicine. The successful implementation of this approach will depend on overcoming current barriers and fostering a collaborative environment that prioritizes patient safety and equitable access to pharmacogenomic advancements.

REFERENCES

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, Walley TJ, Farrar K, Park BK, Breckenridge AM. Adverse drug reactions as cause of admission to hospital: prospective analysis of 18 820 patients. Bmj. 2004 Jul 1;329(7456):15-9.
2. Rabbur RS, Emmerton L. An introduction to adverse drug reaction reporting systems in different countries. International Journal of Pharmacy Practice. 2005 Mar;13(1):91-100.
3. Classen DC, Pestotnik SL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. Jama. 1997 Jan 22;277(4):301-6.

4. Doan T, Lievano F, Scarazzini L, Schubert C, Hendrickson B, editors. Pharmacovigilance-E-BOOK: Pharmacovigilance-E-BOOK. Elsevier Health Sciences; 2024 Nov 20.
5. Zhang H, Song Y, Xia F, Liu Y, Zhang L, Yang J, Tu H, Long B, Sui J, Wang Y. Adverse event profile of crizotinib in real-world from the FAERS database: a 12-year pharmacovigilance study. BMC Pharmacology and Toxicology. 2025 Mar 14;26(1):61.
6. Relling MV, Evans WE. Pharmacogenomics in the clinic. Nature. 2015 Oct 15;526(7573):343-50.
7. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine. 2017 Feb 1;19(2):215-23.
8. Jose J, Cox AR, Bate A. Introduction to Drug Safety and Pharmacovigilance. InPrinciples and Practice of Pharmacovigilance and Drug Safety 2024 Aug 6 (pp. 3-30). Cham: Springer International Publishing.
9. Cacabelos R, Naidoo V, Corzo L, Cacabelos N, Carril JC. Genophenotypic factors and pharmacogenomics in adverse drug reactions. International journal of molecular sciences. 2021 Dec 10;22(24):13302.
10. Jeiziner C, Suter K, Wernli U, Barbarino JM, Gong L, Whirl-Carrillo M, Klein TE, Szucs TD, Hersberger KE, Meyer Zu Schwabedissen HE. Pharmacogenetic information in Swiss drug labels–a systematic analysis. The pharmacogenomics journal. 2021 Aug;21(4):423-34.
11. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, Van Schaik RH, Schalekamp T, Touw DJ, van der Weide J. Pharmacogenetics: from bench to byte—an update of guidelines. Clinical Pharmacology & Therapeutics. 2011 May;89(5):662-73.
12. Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy—recent progress and future developments. The AAPS journal. 2018 Jan;20:1-6.
13. Ventola CL. Role of pharmacogenomic biomarkers in predicting and improving drug response: part 1: the clinical significance of pharmacogenetic variants. Pharmacy and Therapeutics. 2013 Sep;38(9):545.
14. Rettie AE, Jones JP. Clinical and toxicological relevance of CYP2C9: drug-drug interactions and pharmacogenetics. Annu. Rev. Pharmacol. Toxicol.. 2005 Feb 10;45(1):477-94.

15. Zhou S, Skaar DJ, Jacobson PA, Huang RS. Pharmacogenomics of medications commonly used in the intensive care unit. Frontiers in Pharmacology. 2018 Dec 4;9:1436.
16. Pirmohamed M. Pharmacogenomics: current status and future perspectives. Nature Reviews Genetics. 2023 Jun;24(6):350-62.
17. Hughes DA, Vilar FJ, Ward CC, Alfirevic A, Park BK, Pirmohamed M. Cost-effectiveness analysis of HLA B* 5701 genotyping in preventing abacavir hypersensitivity. Pharmacogenetics and Genomics. 2004 Jun 1;14(6):335-42.
18. Innocenti F, Kroetz DL, Schuetz E, Dolan ME, Ramírez J, Relling M, Chen P, Das S, Rosner GL, Ratain MJ. Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics. Journal of Clinical Oncology. 2009 Jun 1;27(16):2604-14.
19. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011 Sep 1;12(9):1321-36.
20. Russell LE, Claw KG, Aagaard KM, Glass SM, Dasgupta K, Nez FL, Haimbaugh A, Maldonato BJ, Yadav J. Insights into pharmacogenetics, drug-gene interactions, and drug-drug-gene interactions. Drug Metabolism Reviews. 2024 Aug 16:1-9.
21. Lavertu A, Vora B, Giacomini KM, Altman R, Rensi S. A new era in pharmacovigilance: toward real-world data and digital monitoring. Clinical Pharmacology & Therapeutics. 2021 May;109(5):1197-202.
22. Alomar M, Tawfiq AM, Hassan N, Palaian S. Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future. Therapeutic advances in drug safety. 2020 Aug;11:2042098620938595.
23. Maqbool M, Dar MA, Rasool S, Bhat AU, Geer MI. Drug safety and Pharmacovigilance: An overview. J Drug Deliv Ther. 2019 Mar 2;9:543-8.
24. Raschi E, Del Re M, Conti V, Roncato R, Donnini S, Marzocco S, Ianaro A, Filippelli A. Pharmacovigilance, drug interactions, pharmacogenetics and therapeutic drug monitoring of anticancer agents: a valuable support for clinical practice. PHARMADVANCES. 2021;3(3):548-67.
25. Loo TT, Ross CJ, Sistonen J, Visscher H, Madadi P, Koren G, Hayden MR, Carleton BC. Pharmacogenomics and active surveillance for serious adverse drug reactions in children. Pharmacogenomics. 2010 Sep 1;11(9):1269-85.
26. Trifirò G, Crisafulli S. A new era of pharmacovigilance: future challenges and opportunities. Frontiers in Drug Safety and Regulation. 2022 Feb 25;2:866898.

27. Orzetti S, Tommasi F, Bertola A, Bortolin G, Caccin E, Cecco S, Ferrarin E, Giacomin E, Baldo P. Genetic therapy and molecular targeted therapy in oncology: safety, pharmacovigilance, and perspectives for research and clinical practice. International Journal of Molecular Sciences. 2022 Mar 10;23(6):3012.
28. Clark DW, Donnelly E, Coulter DM, Roberts RL, Kennedy MA. Linking pharmacovigilance with pharmacogenetics. Drug safety. 2004 Dec;27:1171-84.
29. Sirot EJ, van der Velden JW, Rentsch K, Eap CB, Baumann P. Therapeutic drug monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Safety. 2006 Sep;29:735-68.
30. Chen P, Lin JJ, Lu CS, Ong CT, Hsieh PF, Yang CC, Tai CT, Wu SL, Lu CH, Hsu YC, Yu HY. Carbamazepine-induced toxic effects and HLA-B* 1502 screening in Taiwan. New England Journal of Medicine. 2011 Mar 24;364(12):1126-33.
31. Huang ZP, Wang DZ. miR-22 in cardiac remodeling and disease. Trends in cardiovascular medicine. 2014 Oct 1;24(7):267-72.
32. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine. 2017 Feb 1;19(2):215-23.
33. Lazaridis KN, MCAllister TM, Babovic-Vuksanovic D, Beck SA, Borad MJ, Bryce AH, Chanan-Khan AA, Ferber MJ, Fonseca R, Johnson KJ, Klee EW. Implementing individualized medicine into the medical practice. InAmerican Journal of Medical Genetics Part C: Seminars in Medical Genetics 2014 Mar (Vol. 166, No. 1, pp. 15-23).
34. Zamek-Gliszczynski MJ, Lee CA, Poirier A, Bentz J, Chu X, Ellens H, Ishikawa T, Jamei M, Kalvass JC, Nagar S, Pang KS. ITC recommendations for transporter kinetic parameter estimation and translational modeling of transport-mediated PK and DDIs in humans. Clinical Pharmacology & Therapeutics. 2013 Jul;94(1):64-79.
35. Pirmohamed M, Burnside G, Eriksson N, Jorgensen AL, Toh CH, Nicholson T, Kesteven P, Christersson C, Wahlström B, Stafberg C, Zhang JE. A randomized trial of genotype-guided dosing of warfarin. New England Journal of Medicine. 2013 Dec 12;369(24):2294-303.
36. Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. Cytochrome p-450 polymorphisms and response to clopidogrel. New England journal of medicine. 2009 Jan 22;360(4):354-62.

37. Nishida N, Hirai M, Kawamura S, Oota H, Umetsu K, Kimura R, Ohashi J, Tajima A, Yamamoto T, Tanabe H, Mano S. The history of human populations in the Japanese Archipelago inferred from genome-wide SNP data with a special reference to the Ainu and the Ryukyuan populations. Journal of human genetics. 2012 Nov 8;57:787-95.
38. Tata EB, Ambele MA, Pepper MS. Barriers to implementing clinical pharmacogenetics testing in Sub-Saharan Africa. A critical review. Pharmaceutics. 2020 Aug 26;12(9):809.
39. Zhou Y, Lauschke VM. Next-generation sequencing in pharmacogenomics–fit for clinical decision support?. Expert Review of Clinical Pharmacology. 2024 Mar 3;17(3):213-23.
40. Anfinogenova ND, Stepanov VA, Chernyavsky AM, Karpov RS, Efimova EV, Novikova OM, Trubacheva IA, Falkovskaya AY, Maksimova AS, Ryumshina NI, Shelkovnikova TA. Clinical Significance and Patterns of Potential Drug–Drug Interactions in Cardiovascular Patients: Focus on Low-Dose Aspirin and Angiotensin-Converting Enzyme Inhibitors. Journal of Clinical Medicine. 2024 Jul 23;13(15):4289.
41. Huebner T, Steffens M, Linder R, Fracowiak J, Langner D, Garling M, Falkenberg F, Roethlein C, Gomm W, Haenisch B, Stingl J. Influence of metabolic profiles on the safety of drug therapy in routine care in Germany: protocol of the cohort study EMPAR. BMJ open. 2020 Apr 1;10(4):e032624.
42. Twesigomwe D, Mazhindu TA, Nagy M, Agesa G, Scholefield J, Masimirembwa C. Pharmacogenomics in Africa: A Potential Catalyst for Precision Medicine in Genetically Diverse Populations. Annual Review of Genomics and Human Genetics. 2025 Mar 27;26.
43. Rajakumari K, Shri KK, Logesh R, Meenambiga SS, Vivek P, Romauld SI. Global Perspectives on Pharmacogenomics and Drug Discovery. InGenomics-Driven Drug Discovery Through Pharmacogenomics 2025 (pp. 123-166). IGI Global Scientific Publishing.
44. Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing–from byte to bedside. Drug Metabolism Reviews. 2021 Apr 3;53(2):253-78.
45. Sharafshah A, Motovali-Bashi M, Keshavarz P, Blum K. Synergistic Epistasis and Systems Biology Approaches to Uncover a Pharmacogenomic Map Linked to Pain, Anti-Inflammatory and Immunomodulating Agents (PAImа) in a Healthy Cohort. Cellular and Molecular Neurobiology. 2024 Dec;44(1):74.
46. Goodsaid FM, Amur S, Aubrecht J, Burczynski ME, Carl K, Catalano J, Charlab R, Close S, Cornu-Artis C, Essioux L, Fornace AJ. Voluntary exploratory data submissions to the US FDA

and the EMA: experience and impact. Nature reviews Drug discovery. 2010 Jun;9(6):435-45.

47. Shekhani R, Steinacher L, Swen JJ, Ingelman-Sundberg M. Evaluation of current regulation and guidelines of pharmacogenomic drug labels: opportunities for improvements. Clinical Pharmacology & Therapeutics. 2020 May;107(5):1240-55.
48. Kashoki M, Hanaizi Z, Yordanova S, Veselý R, Bouygues C, Llinares J, Kweder SL. A comparison of EMA and FDA decisions for new drug marketing applications 2014–2016: concordance, discordance, and why. Clinical Pharmacology & Therapeutics. 2020 Jan;107(1):195-202.
49. Koutsilieri S, Tzioufa F, Sismanoglou DC, Patrinos GP. Unveiling the guidance heterogeneity for genome-informed drug treatment interventions among regulatory bodies and research consortia. Pharmacological Research. 2020 Mar 1;153:104590.
50. Lee M, Han JM, Lee J, Oh JY, Kim JS, Gwak HS, Choi KH. Comparison of pharmacogenomic information for drug approvals provided by the national regulatory agencies in Korea, Europe, Japan, and the United States. Frontiers in Pharmacology. 2023 Jun 8;14:1205624.
51. Dalpé G, Joly Y. Towards precision medicine: The legal and ethical challenges of pharmacogenomics. InRoutledge handbook of medical law and ethics 2014 Sep 19 (pp. 339-366). Routledge.
52. García-García I, Seco-Meseguer E, Borobia AM, Carcas-Sansuán AJ. Implementing pharmacogenetics in clinical trials: considerations about current methodological, ethical, and regulatory challenges. Expert Review of Clinical Pharmacology. 2024 Jan 2;17(1):1-0.
53. March R, Cheeseman K, Doherty M. Pharmacogenetics–legal, ethical and regulatory considerations. Pharmacogenomics. 2001 Nov 1;2(4):317-27.
54. Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. Journal of pharmaceutical sciences. 2017 Sep 1;106(9):2368-79.
55. Eichmeyer J, Rogers S, Formea CM, Giri J, Jones JS, Schnettler E, Schmidlen T, Glogowski E, Kurz RN. PARC report: a perspective on the state of clinical pharmacogenomics testing. Pharmacogenomics. 2020 Jul 1;21(11):809-20.
56. Kabbani D, Akika R, Wahid A, Daly AK, Cascorbi I, Zgheib NK. Pharmacogenomics in practice: a review and implementation guide. Frontiers in Pharmacology. 2023 May 18;14:1189976.

57. Papachristos A, Cusato J, Nair S, Maggo S, Suppiah V. Utilization of pharmacogenomics in clinical practice. Frontiers in Genetics. 2024 Aug 20;15:1470698.
58. Shuja N. Pharmacogenomics and Asia: Bridging Scientific Potential with Access Equity: Pharmacogenomics and Access in Asia. DEVELOPMENTAL MEDICO-LIFE-SCIENCES. 2025 Apr 24;2(3):1-4.
59. Minji KO, Yumin KI, Hanbyeol CH, Ho-Keun CH. Role of CYP2D6 Gene Variants and Family History in Personalized Antidepressant Treatments for Depression. Korean Journal of Clinical Laboratory Science. 2025;57(1):16-26.
60. Dunnenberger HM, Crews KR, Hoffman JM, Caudle KE, Broeckel U, Howard SC, Hunkler RJ, Klein TE, Evans WE, Relling MV. Preemptive clinical pharmacogenetics implementation: current programs in five US medical centers. Annual review of pharmacology and toxicology. 2015 Jan 6;55(1):89-106.
61. Tishkoff SA, Verrelli BC. Patterns of human genetic diversity: implications for human evolutionary history and disease. Annual review of genomics and human genetics. 2003 Sep;4(1):293-340.
62. Stanek EJ, Sanders CL, Taber KJ, Khalid M, Patel A, Verbrugge RR, Agatep BC, Aubert RE, Epstein RS, Frueh FW. Adoption of pharmacogenomic testing by US physicians: results of a nationwide survey. Clinical Pharmacology & Therapeutics. 2012 Mar;91(3):450-8.
63. Caudle KE, Dunnenberger HM, Freimuth RR, Peterson JF, Burlison JD, Whirl-Carrillo M, Scott SA, Rehm HL, Williams MS, Klein TE, Relling MV. Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC). Genetics in Medicine. 2017 Feb 1;19(2):215-23.
64. Overby CL, Kohane I, Kannry JL, Williams MS, Starren J, Bottinger E, Gottesman O, Denny JC, Weng C, Tarczy-Hornoch P, Hripcsak G. Opportunities for genomic clinical decision support interventions. Genetics in Medicine. 2013 Oct;15(10):817-23.
65. Kho AN, Hayes MG, Rasmussen-Torvik L, Pacheco JA, Thompson WK, Armstrong LL, Denny JC, Peissig PL, Miller AW, Wei WQ, Bielinski SJ. Use of diverse electronic medical record systems to identify genetic risk for type 2 diabetes within a genome-wide association study. Journal of the American Medical Informatics Association. 2012 Mar 1;19(2):212-8.
66. Ahire YS, Patil JH, Chordiya HN, Deore RA, Bairagi VA. Advanced applications of artificial intelligence in pharmacovigilance: Current trends and future perspectives. J Pharm Res. 2024 Jan;23(1):23-33.

67. Chowdhury IQ. Artificial Intelligence in Pharmacy: Innovations, Applications, and Future Emerging Challenges.
68. Dimitsaki S, Natsiavas P, Jaulent MC. Applying AI to Structured Real-World Data for Pharmacovigilance Purposes: Scoping Review. Journal of Medical Internet Research. 2024 Dec 30;26:e57824.
69. Taherdoost H, Ghofrani A. AI and the Evolution of Personalized Medicine in Pharmacogenomics. Intelligent Pharmacy. 2024 Aug 20.
70. Rajakumari K, Shri KK, Logesh R, Meenambiga SS, Vivek P, Romauld SI. Global Perspectives on Pharmacogenomics and Drug Discovery. InGenomics-Driven Drug Discovery Through Pharmacogenomics 2025 (pp. 123-166). IGI Global Scientific Publishing.
71. Upadhyay J, Nandave M, Kumar A. Role of Artificial Intelligence in Pharmacovigilance. InPharmacovigilance Essentials: Advances, Challenges and Global Perspectives 2024 Apr 4 (pp. 347-363). Singapore: Springer Nature Singapore.
72. Silva L, Pacheco T, Araújo E, Duarte RJ, Ribeiro-Vaz I, Ferreira-da-Silva R. Unveiling the future: precision pharmacovigilance in the era of personalized medicine. International Journal of Clinical Pharmacy. 2024 Jun;46(3):755-60.
73. Badria FA, Elgazar AA. Optimizing Pharmacovigilance in an Era of Accelerating Innovation.
74. Al-Remawi M, Rahem RA. Applications of AI in Biomedical Genomics and Pharmaceuticals. In2024 2nd International Conference on Cyber Resilience (ICCR) 2024 Feb 26 (pp. 1-5). IEEE.
75. Joshi M, Patel BM. Pre-clinical and Clinical Studies, Pharmacovigilance, Pharmacogenomics, and Commercialization of Pharmaceutical Products. InAdvances in Pharmaceutical Product Development 2025 Mar 19 (pp. 423-443). Singapore: Springer Nature Singapore.